Commentary

Predicting QoL in Colorectal Cancer Survivors

Publish date: November 19, 2012

 

I couldn’t agree more.

Dr. Freed is a psychologist in Santa Barbara, Calif., and a medical journalist.

Pages

Recommended Reading

Management of Zollinger-Ellison May Depend on Presence of Tumors
MDedge Hematology and Oncology
Evidence Mounts for Continuing Bevacizumab After Colorectal Cancer Progresses
MDedge Hematology and Oncology
Lower Treatment Cost Doesn't Mean Lower Quality Care
MDedge Hematology and Oncology
Concurrent Sorafenib and SBRT Too Toxic in Liver Cancer
MDedge Hematology and Oncology
Fatty Liver Disease Cited for Rise in Hepatocellular Carcinoma
MDedge Hematology and Oncology
Sanofi Discounts Cancer Drug by 50% After Backlash
MDedge Hematology and Oncology
Oncologist Roundtable: Is the Zaltrap Reversal a 'Watershed Moment' in Drug Pricing?
MDedge Hematology and Oncology
Antivirals Linked to Lower Risk of Liver Cancer Return
MDedge Hematology and Oncology
Earlier End-of-Life Talks Deter Aggressive Care of Terminal Cancer Patients
MDedge Hematology and Oncology
Community Oncology Podcast - Cetuximab and FOLFIRI in colon cancer
MDedge Hematology and Oncology